NCT06814301 - Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients (INMUNOEND) | Biotech Hunter

Enrollment

123

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

September 30, 2027

Conditions

Cytomegalovirus Cell Mediated ImmunityStem Cell Transplantation, Hematopoietic

Interventions

DIAGNOSTIC_TEST

Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV

A first determination will be made pre-HCT, followed by subsequent determinations at +30, +60, +90, +120, +150, +180, and +200 days post-HCT, as well as at the end of prophylaxis with Letermovir

DIAGNOSTIC_TEST

Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV

A first determination will be made pre-HCT, followed by subsequent determinations at +30, +60, +90, +120, +150, +180, and +200 days post-HCT, as well as at the end of prophylaxis with LTV

Trial Locations (1)

14004

Hospital Universitario Reina Sofía, Córdoba